Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2010

View Archived Issues

CAT promoter polymorphism is linked to risk of vitiligo in Chinese individuals

Dutch scientists patent new modulators of glycoprotein hormone LH receptor

FDA sets PDUFA date for Endo Pharma's new formulation of long-acting oxymorphone hydrochloride

Curemark receives grant for development of CM-AT

Phase II data show benefit of pentoxifylline in nonalcoholic steatohepatitis

PLX-5622 reduces disease activity in a model of rheumatoid arthritis

In vivo data support potential of galantamine for treatment of obesity and related complications

Long-term Arikace therapy is well tolerated in patients with CF and P. aeruginosa infection

ECLIPSE trial compares Epanova with Lovaza

Nuvo Research presents topline phase II data on WF-10 in allergic rhinitis

Enrollment completed in Nabi Biopharma' second phase III NicVAX trial

FDA clears phase II trial of MultiStem in ulcerative colitis

TransTech Pharma and High Point Pharmaceuticals receive grants for development projects

Novel cannabinoid CB2 receptor ligands claimed by sanofi-aventis

Shire finalizes acquisition of Movetis

Infinity Pharma patents new fatty-acid amide hydrolase 1 inhibitors

Actelion Pharmaceuticals discloses novel antibacterial agents

Kyorin Pharma claims new muscarinic M3 receptor antagonists

Xoma receives grants to advance ongoing MAb development projects

MAP Pharmaceuticals reports results from Levadex QT trial

BioInvent receives FDA clearance for phase II trial of BI-204

Enanta Pharma discloses new HCV NS5 inhibitors

Apogee Biotech to begin phase I ABC-294640 development in several types of cancer

NeoPharm and Insys Therapeutics complete merger

Patient screening complete for phase III rhGAD65 trial in type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...